Ractigen Therapeutics’ RAG-21 Receives FDA Orphan Drug Designation for Treating FUS-ALS
Ractigen Therapeutics' RAG-21 Receives FDA Orphan Drug Designation for Treating FUS-ALS Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, tod ...